Effects of a combination treatment of KD5040 and (L)-dopa in a mouse model of Parkinson’s disease

BACKGROUND: Although the dopamine precursor L-3, 4-dihydroxyphenylalanine ((l)-dopa) remains the gold standard pharmacological therapy for patients with Parkinson’s disease (PD), long-term treatment with this drug has been known to result in several adverse effects, including (l)-dopa-induced dyskin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Sora, Song, Taek-Jin, Park, Seong-Uk, Jeon, Songhee, Kim, Jongpil, Oh, Joo-Young, Jang, Jaehwan, Hong, Sanhwa, Song, Min-A, Shin, Hye-Seoung, Jung, Young-Rim, Park, Hi-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395961/
https://www.ncbi.nlm.nih.gov/pubmed/28424060
http://dx.doi.org/10.1186/s12906-017-1731-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395961/
https://www.ncbi.nlm.nih.gov/pubmed/28424060
http://dx.doi.org/10.1186/s12906-017-1731-2

Ejemplares similares